# R03 v2 独立来源与贡献审查

- Reviewer assignment: `/root/r03_v2_source_review`
- Artifact: `research/delta-discovery-2026-10-08/repairs/R03_COUPLED_HORIZON_SAFETY.v2.md`
- Artifact SHA256: `4c083cba9b45ebb27d82996aff894836ec832b993632e9992645b3a865fb5761`
- Source audit: `research/delta-discovery-2026-10-08/sources/REPAIR_R03_V2_COUPLED_HORIZON_SOURCE_AUDIT.md`
- Source-audit SHA256: `ddae48a2983ef030a2f75f7df763e35b20a54344adb7722e3d456e5807d8c844`
- Decision: **ACCEPT — useful conditional control/theory boundary; not a candidate**

The first exact-byte review found one blocking omission: the multi-action budget inequality was not sufficient without `K epsilon_mu<=1`. The final artifact states `0<epsilon_mu<=1/K` and the binary `<=1/2` specialization; final re-review accepted it.

Substantive source conclusions:

1. SEPEC, Safe Optimal Design, stage-wise constrained bandits, CLUCB/SEA and ordinary OPE already cover safe/cost-constrained logging and variance tradeoffs. The propensity optimization is not new.
2. The project's already reviewed small-gain/protected-fiber source packet and primary discrete-time small-gain source cover the dynamical bounding machinery. RTRL/UORO/KF-RTRL/OK/SnAp/e-prop and the closed-loop-rank audit cover full sensitivity and compressed approximations.
3. The remaining narrow interface is `Delta rank-one injection × complete coupled incremental gain × positivity feasibility`. Bounded search has not certified that exact formula as previously written, but no algorithmic novelty or same-budget advantage is shown; exact-combination novelty coverage remains unexhausted.
4. Stored primary/author-interface audits support the SEAL, ACL/SRWM, HOPE and Titans boundaries. SEAL's pinned repository is not a v2 reproduction; HOPE author code was not located and the observed Titans author repository was empty. No third-party implementation filled those gaps.
5. LongMemEval v1/v2, SEAL continual, CITB/TRACE, bAbI and LAMBADA measure endpoints/BWT but do not natively provide joint propensity, protected-validity, uniform-gain and paired-counterfactual labels. The measurement gap is correctly preserved.

Residual limitations are explicit: common-exogenous-path safety is not free-running total effect; protected validity and uniform tube/gain bounds require extra evidence; expected safety is not realized safety; all efficacy is unknown and unexecuted.

Final disposition: retain as R03 attempt 2 conditional control/theory result, zero new candidates. Counts stay 5 historical / 0 active / 0 admitted / 0 selected.
